This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into the data from the Phase 3 CORALreef clinical trial of Enlicitide in patients with hyperlipidemia.

Ticker(s): MRK

Who's the expert?

Institution: Penn Medicine

  • Clinical Associate Professor at the University of Pennsylvania’s Perelman School of Medicine, specializing in preventive cardiology and clinical lipidology at Penn Heart and Vascular Center.

  • Director of Education for Preventive Cardiology and co-director of the Preventive Cardiology Fellowship at Pennsylvania Hospital, leading research on novel lipid disorder therapies.

  • Fellow of the National Lipid Association and American College of Physicians, authoring over 50 peer-reviewed articles on cardiovascular risk and apolipoprotein B management.

Interview Goal
This call will feature a discussion on the current standard of care and the potential of Enlicitide, an oral PCSK9 inhibitor being developed by Merck for the treatment of hyperlipidemia.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.